Since 2014 Hershey (NYSE:HSY) has been struggling a lot with its foreign operations. This has been due to the facts that the general business environment has been rather weak in foreign countries where Hershey is operating, that a strong dollar has hurt the sales and especially that the Chinese market has proved to be much more difficult than expected.
One other thing that I am even more worried about is the way the current management at Hershey is using adjusted earnings in its earnings releases. I do not know about the rest of the investors, but at least for me, when management is constantly talking about adjusted earnings instead of actual earnings, it is a warning sign. I can fully understand one-time business costs, such as transactions costs related to a major acquisition. In that type of a situation it is perfectly fine to use adjusted earnings because they give more visibility about the true earnings power of a company. However, when a company starts to constantly categorize regular annual costs as one-time costs, like Hershey is doing with business realignment costs, you should be very worried. In the case of Hershey, I would consider the business realignment costs as regular costs as they have been there for several years. This is a bit like when Warren Buffett is recommending that investors walk away if management is constantly referring to EBIT figures.
Best Warren Buffett Stocks To Buy Right Now: Conn's, Inc.(CONN)
- [By Peter Graham]
A long term performance chart shows shares of Best Buy Co outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):
- [By Monica Gerson]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday’s regular session.
Pier 1 Imports Inc (NYSE: PIR) Dec16 5.0 Puts Sweep: 1191 @ ASK $0.80: 1354 traded vs 102 OI: $5.32 Ref
Alcoa Inc (NYSE: AA) Jul16 9.5 Puts Sweep: 1494 @ ASK $0.13: 14k traded vs 6682 OI: $10.09 Ref
Sarepta Therapeutics Inc (NASDAQ: SRPT) Jul16 10.0 Puts: 3536 @ ASK $0.50: 5506 traded vs 54k OI: Earnings 8/4 $22.50 Ref
Tableau Software Inc (NYSE: DATA) Jul16 47.5 Puts Sweep: 837 @ ASK $0.30: 995 traded vs 37 OI: Earnings 8/3 $50.60 Ref
Yandex NV (NASDAQ: YNDX) Aug16 18.0 Puts Sweep: 532 @ ASK $0.30: 2143 traded vs 78 OI: Earnings 7/28 Before Open $22.02 Ref
Wolverine World Wide, Inc. (NYSE: WWW) Aug16 22.5 Puts: 719 @ ASK $1.35: 1032 traded vs 0 OI: Earnings 7/19 $22.22 Ref
Conn's Inc (NASDAQ: CONN) Jan17 5.0 Puts Sweep: 605 @ ASK $0.85: 1355 traded vs 3132 OI: $7.16 Ref
Posted-In: Huge Put PurchasesNews Options Markets
- [By Lisa Levin]
Wednesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Conn's Inc (NASDAQ: CONN) and Wyndham Worldwide Corporation (NYSE: WYN).
Best Warren Buffett Stocks To Buy Right Now: Catalyst Biosciences, Inc. (CBIO)
- [By Ashley Moore]
Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:
Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%
- [By Lisa Levin]
Shares of Catalyst Biosciences Inc (NASDAQ: CBIO) were down around 27 percent to $5.36. Catalyst Biosciences reported the pricing of $18 million offering of Class A units at $5 per unit
- [By Lisa Levin]
Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia
Best Warren Buffett Stocks To Buy Right Now: Meritage Corporation(MTH)
- [By Jason Hall]
WhenMeritage Homes Corp(NYSE:MTH) last reported earnings to wrap up fiscal 2016, it left investors with reason to be concerned. The company finished the year with strong 15% home-closing revenue growth in the fourth quarter, 19% home-closing revenue growth for the full year, and a 15% jump in earnings per share for the year. Unfortunately, the homebuilder reported that its unit sales, and that its backlog of homes on order, were down from the year-ago period in the fourth quarter — not a positive metric considering the general strength of the new homes market and the company’s success in expanding and growing in recent years.
Best Warren Buffett Stocks To Buy Right Now: Southern Company (The)(SO)
- [By Dustin Parrett]
Natural gas just claimed another victory over clean coal, as Southern Co. (NYSE: SO) announced on June 28 it’s converting its failed $7.1 billion clean coal power plant into a natural gas-fired facility.
- [By Paul Ausick]
The Southern Co. (NYSE: SO) traded down about 1.9% Thursday and posted a new 52-week low of $45.08 after closing Wednesday at $45.96. The 52-week high is $53.51. Volume was about 5.4 million, about 15% above the daily average of around 4.8 million shares. The company had no specific news Thursday.
- [By Paul Ausick]
The Southern Co. (NYSE: SO) traded down about 2.9% Wednesday and posted a new 52-week low of $45.81 after closing Tuesday at $47.20. The 52-week high is $53.51. Volume was about 5.5 million, about 15% above the daily average of around 4.8 million shares. The company had no specific news Wednesday.
- [By ]
Under a single-payer system, healthcare becomes a regulated utility much like electricity with just a few large, best-in-class players. Athenahealth (Nasdaq: ATHN) could combine with Walgreen Boots Alliance (NYSE: WBA). Maybe each monolith will cover a specific region like Southern Company (NYSE: SO) and Consolidated Edison (NYSE: ED).
- [By Paul Ausick]
The Southern Co. (NYSE: SO) traded down about 1.7% Friday and posted a new 52-week low of $44.46 after closing Thursday at $45.25. The 52-week high is $53.51. Volume was over 6 million, about 20% above the daily average of around 4.8 million shares. The company was dropped from Neutral to Sell at Goldman Sachs on Thursday.
Best Warren Buffett Stocks To Buy Right Now: Westinghouse Air Brake Technologies Corporation(WAB)
- [By WWW.MONEYSHOW.COM]
Westinghouse Air Brake Technologies Corporation (WAB) scores highly based on my Warren Buffett-based model, which is based on the book Buffettology, and also the Peter Lynch-inspired approach that uses the method outlined by Lynch in One Up on Wall Street.
Best Warren Buffett Stocks To Buy Right Now: Coherus BioSciences, Inc.(CHRS)
- [By Lisa Levin] Gainers
Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Ben Levisohn]
Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:
Agence France-Presse/Getty Images
The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.
- [By Lisa Levin]
Coherus Biosciences Inc (NASDAQ: CHRS) shares shot up 23 percent to $13.70 after the company announced plans to raise up to $150 million in a private placement.